close
MENU
Business
2 mins to read

Diagnostics firm Pictor expects revenue boom from Covid partnership

The company is targeting $10m in revenue next year.

Andrew Bevin Wed, 29 Sep 2021

Auckland-based biotech firm Pictor says a new partnership with Scienion, a subsidiary of Stockholm listed Bico, to commercialise a high-throughput Covid-19 antibody testing system will take its business to new revenue heights.

The companies will incorporate Scienion’s CL2 sciREADER system into

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Andrew Bevin Wed, 29 Sep 2021
Contact the Writer: andrew@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Diagnostics firm Pictor expects revenue boom from Covid partnership
Business,
89113
true